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Oral glucose tolerance test
Background: The aim of this study is to examine the effect of an intensive CR program early after coronary artery
bypass grafting on glucometabolic state of non-diabetic patients with CAD.
Methods: 60 patients were included in the study. All patients underwent Oral Glucose Tolerance Test (OGTT), Ho-
meostasis Model Assessment (HOMA) Index and Six Minutes Walking Test at baseline and at the end of CR. The
patients were then included in a 3-month follow-up program.
Results: At baseline 61% of the patients had normal fasting glucose, while after OGTT 28.3% had normal glucose
tolerance, 41.6% had impaired glucose tolerance (IGT), and 30.1% had type 2 diabetes mellitus (T2DM). At the
end of the CR program the number of patients with T2DM was signiﬁcantly lower (−22%, p b 0.05) while the
number of normal glucose tolerance patients had signiﬁcantly increased (+26%; p b 0.05). T2DM and IGT pa-
tients showed worse performances at Six Minutes Walking Test than normal glucose tolerance patients at base-
line but had a similar improvement after 4 weeks of training. After 3 months follow-up fasting blood glucose,
insulin levels and HOMA index were increased compared to 4 week values, but were lower than baseline.
Conclusion: OGTT is important to evaluate glucometabolic state of CAD patients. Intensive CR improves
glucometabolic state and insulin resistance in CAD patients with impaired glucose metabolism.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
It iswell known that individualswith type 2 diabetesmellitus (T2DM)
have an increased cardiovascular morbidity and mortality [1,2] and that
patients with coronary artery disease (CAD) and T2DMhave signiﬁcantly
worse outcomes than patients with CAD but without diabetes [3–6]. Im-
paired glucose tolerance (IGT) is also a strong risk factor for future cardio-
vascular events as fatal or non-fatal re-infarction, stroke, and severe heart
failure in patients with recent myocardial infarction [7]. The glu-
cometabolic state of patients admitted to the coronary care units with
acute myocardial infarction, with or without diagnosis of diabetes, is an
important marker of risk for long-term mortality. The Glucose in Acute
Myocardial Infarction (GAMI) study [8] suggested that patientswithmyo-
cardial infarction have a high prevalence of previously unknown T2DM
and IGT and recent data from the EURO Heart Survey on Diabetes [9]
have shown a high prevalence of T2DM or IGT in patients with chronic
CAD.
Nearly 20% of patients with myocardial infarction have a previously
diagnosed T2DM [2,10]; however if an Oral Glucose Tolerance Test39 0652252478.
aminiti).
eliability and freedom frombias
. This is an open access article under(OGTT) is performed, the prevalence of diabetes becomes higher, pre-
sumably as high as 40–45% [8,11].
Patients with CAD undergoing cardiac rehabilitation (CR) early after
coronary artery bypass grafting have often impaired glucose metabo-
lism, irrespective of a previous history of diabetes, as a consequence of
that stressful condition. OGTT is more accurate than fasting blood glu-
cose alone in order to identify CAD patients with impaired glucose me-
tabolism [12,13]. Detection of impaired glucose metabolism during
hospitalization in patients with CAD in the acute and post-acute phases
may therefore be a target for novel secondary preventive efforts.
Among preventive interventions, exercise training has a well
established role on treating impaired glucosemetabolism as underlined
by guidelines in patients with T2DM and IGT.
The aim of our study was to examine the real prevalence of glucose
metabolism alterations in patients with CAD, without previous diagno-
sis of T2DM, and to evaluate the potential beneﬁcial effect of physical
training on glucometabolic state of these patients.
2. Methods
From January 2010 to June 2011 we screened 136 consecutive CAD
patients who were admitted to our CR Unit to undergo a cycle of in-
hospital rehabilitation early after coronary artery bypass (less thanthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tients underwent a cycle of in-hospital rehabilitation that started two
weeks after CABG.
We included in the study patients with no previous history of T2DM,
fasting blood glucose at admission b126 mg/dl, and full ability to start
physical training within three days after admission. Exclusion criteria
were: previous diagnosis of T2DM (it was considered present if the pa-
tient had been informed of this diagnosis and/or was on anti-diabetic
treatment), physical disabilities contraindicating training, ventricular
arrhythmias, primary valve disease, pericardial effusion, severe chronic
obstructive pulmonary disease and claudication.
Demographic and clinical data were recorded at admission to our
Unit; on the ﬁrst morning after admission fasting blood glucose,
serum lipid proﬁle (total cholesterol, high density lipoprotein (HDL)
cholesterol, triglycerides), serum renal and liver function (creatinine,
BUN, uricemia, SGOT, SGPT, γ-GT) and coagulation parameters were
assessed. Low density lipoprotein (LDL) cholesterol was calculated ac-
cording to the Friedewald formula. All patients were tested for physical
abilities. After evaluation of inclusion and exclusion criteria patients
were asked to join the study and to sign the consent formpreviously ap-
proved by the local ethics committee.
At baseline weight, height, body mass index (kg/m2), waist circum-
ference, and systolic and diastolic blood pressure were collected. All pa-
tients underwent an OGTT (ingestion of 75 g of glucose dissolved in
200 ml of water) according to WHO standards, including fasting basal
blood glucose and fasting blood insulin and blood glucose and insulin
measurements 30, 60, 90 and 120 min after glucose load. At baseline
and prior to the OGTT, glycated hemoglobin (HbA1c), inﬂammatory
markers (high sensitivity-C Reactive Protein, IL-6, TNF-α), creatinine
clearance and microalbuminuria were assessed. Insulin resistance was
estimated by the homeostasis model assessment (HOMA) index [14].
A baseline standard 12-lead electrocardiogram and a full transthoracic
echocardiogram were performed for all patients. Functional capacity
was onlymeasured through thedistancewalked at SixMinutesWalking
Test that was performed according to a standardized procedure [15].
The test was supervised by a physical therapist. The patients were
asked to walk at their own maximal pace in a 100 m long hospital cor-
ridor with 10 m signs on the ﬂoor. Every minute a standard phrase of
encouragement was told. The patients were allowed to stop if signs or
symptoms of signiﬁcant distress occurred (dyspnea, angina), though
they were instructed to resume walking as soon as possible. Results of
Six Minutes Walking Test were expressed as distance walked (meters).
After baseline assessment the patients entered a 4 week program of
intensive CR. The physical rehabilitation program was performed ac-
cording to the AHA guidelines: each exercise session included warm-
up, cool-down and ﬂexibility exercises and 30–60 min of aerobic exer-
cise with cycling or treadmill [16] for two exercise sessions every day
for six days/week. The patients underwent an additional assessment
by OGTT, HbA1c, HOMA index, transthoracic echocardiogram and Six
Minutes Walking Test at the end of the in-hospital rehabilitation
program.
All the patientswere then included in anoutpatient physical training
program for 3 further months andwere given a nutritional and exercise
program (walking fast at least 30 min for 3 times/week). At the end of
the 3 month period all the patients underwent a follow-up visit with as-
sessment of bodyweight, height, bodymass index, waist circumference,
fasting glucose and insulin, HBA1c and HOMA index. The patients were
asked to express their compliance to the home-based exercise program
through an exercise questionnaire in which the level of compliance was
considered high/moderate (exercise N 3 times/week) or low (exercise b
3 times/week).
2.1. Deﬁnitions
The glucometabolic state was classiﬁed based on the WHO criteria:
normal glucose tolerance was recognized as a fasting blood glucoseb 110 mg/dl (6.1 mmol/l) and 2-h post-load glucose b 140 mg/dl
(7.8 mmol/l); IGT was deﬁned as fasting blood glucose b 126 mg/dl
(7 mmol/l) and 2 h post load glucose ≥ 140 mg/dl (7.8 mmol/l) and
b200 mg/dl (11.1 mmol/l); and T2DM as fasting blood glucose
≥ 126 mg/dl (7 mmol/l) or a 2 h post load glucose ≥ 200 mg/dl
(11.1 mmol/l). The term abnormal glucose tolerance was used to de-
scribe the presence of newly detected T2DM or IGT.
2.2. Laboratory analysis
2.2.1. Serum inﬂammatory cytokine assessment
Once processed, serum samples were immediately stored at
−80 °C. TNF-α and IL-6 (R&D System) were examined by ELISA meth-
od according to manufacturer's instructions.
2.2.2. Glucose and insulin assessment
Glucose and insulin were measured after an overnight fasting. The
blood samples were collected in 5-ml tubes, immediately placed on
ice, and transferred to the biochemistry laboratory where samples
were processed. Plasma insulin levels were measured by
immunoradiometric assay with a commercially available kit (DiaSorin,
Inc., Reutlinger, Germany).
2.3. Statistical methods
Values were expressed as mean ± SD or as percentages where ap-
propriate. Differences in baseline characteristics between groups were
evaluated by the chi-square and unpaired t test. Within-group changes
in the reported variables were evaluated by the paired t-test or
Wilcoxon signed rank test for non normally distributed variables. Be-
tween group comparisons were performed by the unpaired t-test and
Mann–Whitney rank sum test. All analyseswere performedwith a com-
mercially available statistical package (SPSS for Windows version 12.0,
Chicago, Illinois).
3. Results
136 consecutive CAD patients admitted over a 12 month period
(January 2011 to June 2011) to our Cardiac Rehabilitation Unit, early
after coronary artery bypass grafting (average 5.6 days) were screened
for the study. 37 of these were diabetic, and 39 were unable to start
physical trainingwithin 3 days from admission because of acute compli-
cations or severe physical disability. Sixty patients resulted non diabetic
and were able to start physical training, so they were included in the
study.
At baseline 61% of the patients had normal fasting glucose, 85% of the
patients had body mass index ≥ 25; mean waist circumference of our
sample was 101.7 ± 9.5 cm (23 men N 102 cm, 6 women N 88 cm).
The ﬁrst OGTT was performed 2 weeks after CABG. Basing on baseline
OGTT results, the patients were divided into 3 groups: 17 patients
(28.3%) had normal glucose tolerance, 25 (41.6%) had IGT, and 18
(30.1%) had T2DM.
Clinical characteristics of patients included in the study according to
their glucometabolic state are shown in Table 1. At baseline IGT and
T2DMgroups had higher HOMA index, higher levels ofmicroalbuminuria
and higher blood levels of IL6 and TNF-α than normal glucose tolerance
group.
At the end of 4-week CR program, there were no signiﬁcant changes
on BMI andwaist circumference. According to post-CR OGTT, 55% of the
patients resulted to have normal glucose tolerance, 38% IGT and 7%
T2DM. Overall therewas a signiﬁcant improvement in 2 h glucose levels
(170.2 ± 56.2 mg/dl vs 146.8 ± 54.8 mg/dl; p = 0.002). Fasting glyce-
mia (−8.5%), fasting insulinemia (−34.2%), 2 h insulinemia and glyce-
mia and HOMA index (−44%) signiﬁcantly decreased after 4 weeks CR
(Table 2). High sensitivity C-Reactive Protein signiﬁcantly decreased
compared to baseline. Levels of IL6 and TNF-α also signiﬁcantly
Table 1
Basal characteristics of the population according to glucometabolic state.
Abbreviations: NGT: Normal Glucose Tolerance; IGT: Impaired Glucose Tolerance; T2DM:
Type 2 DiabetesMellitus; BMI: BodyMass Index; 6MWT: Six MinutesWalking Test; BUN:
Blood Urea Nitrogen; HDL chol: High-density lipoprotein cholesterol; LDL chol: Low-








Age 69.4 ± 7 69.8 ± 13 72.3 ± 13
Sex: M/F 15/2 21/4 17/1
Body weight, kg 77.6 ± 13 78.9 ± 13 82.9 ± 13
Waist circumference, cm 101.7 ± 9 102.5 ± 10 104.1 ± 12
BMI, kg/m2 27.6 ± 4 27.4 ± 6 29.0 ± 4
Ejection fraction % 58.2 ± 7 53.6 ± 11 47.3 ± 8
Systolic BP, mm Hg 112.6 ± 10 110.4 ± 12 112 .9 ± 8
Diastolic BP, mm Hg 82.4 ± 12 82.7 ± 21 81.2 ± 19
Resting heart rate, bpm 78 ± 14 80 ± 11 77 ± 16
6MWT, m 344.2 ± 79 291.8 ± 66 265 ± 71
Previous myocardial infarction 7 14 11
Number of vessels involved
(one/two/three)
4/7/6 5/13/7 2/7/9
Hypertension (N) 13 17 15
Dyslipidemia (N) 9 16 14
Atrial ﬁbrillation (N) 4 3 6
Laboratory values
Hemoglobin, gr/dl 11.0 ± 1.5 11.8 ± 2.2 12.1 ± 1.5
Creatinine, mg/dl 1.1 ± 0.2 1.2 ± 0.3 1.1 ± 0.2
BUN, mg/dl 40.7 ± 18 42.1 ± 16 42.9 ± 14
Creatinine clearance, ml/min 80.3 ± 16 80.0 ± 21 79.4 ± 19
Microalbuminuria, mg/die 41.3 ± 12 44.6 ± .14 48.5 ± 11
Uricemia, mg/dl 5.9 ± 2 5.3 ± 2 5.7 ± 1
Alanine transaminase, UI/l 20.8 ± 4 21.4 ± 4 18.3 ± 5
Aspartate transaminase, UI/l 24.5 ± 7 22.5 ± 5 26.1 ± 6
Gamma-GT, UI/L 28.5 ± 7 31.6 ± 4 28.6 ± 5
Triglycerides, mg/dl 148.1 ± 39 146.4 ± 36 154.3 ± 44
Total cholesterol, mg/dl 148.5 ± 32 150.9 ± 37 163.5 ± 41
HDL chol, mg/dl 31.0 ± 5 32.6 ± 7 28.6 ± 4
LDL chol, mg/dl 93.0 ± 38 98.0 ± 41 105.0 ± 34
hs-CRP, mg/l 4.6 ± 1.2 5.5 ± 1.9 7.9 ± 2.2
Therapy
Beta blockers (N) 14 23 14
ACE-inhibitors (N) 16 22 18
Statins (N) 13 21 13
Calcium channel antagonists (N) 6 9 6
Antiplatelet agents (N) 17 25 18
Diuretics (N) 11 18 10
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respectively) after 4-week training program. There was a statistically
signiﬁcant correlation between changes in IL6 and HOMA index (r =
0.42; p b 0.05). CRP, IL6 and TNF were not related to fasting blood
glucose.Table 2
Changes observed onmetabolic parameters at 4 weeks and 12 weeks in the overall study-
population; inﬂammatory markers at baseline and 4 weeks in the overall study-
population.
Abbreviations: BMI: Body Mass Index; HOMA index: Homeostasis Model Assessment
Index. HbA1c: glycated hemoglobin.
Basal 4 weeks 12 weeks
BMI, kg/m2 29.8 ± 3.4 29.6 ± 2.7 31.4 ± 3.5
HOMA index 3.0 ± 1.6 1.7 ± 0.8⁎ 2.3 ± 1.2⁎⁎
Fructosamine, μm/l 269 ± 34.9 260 ± 19.9 328 ± 48.1⁎⁎
Fasting insulinemia, μU/ml 12.3 ± 3.5 8.1 ± 4.0⁎ 9.5 ± 4.4
Fasting glycemia, mg/dl 95.6 ± 17.3 87.5 ± 10.8⁎ 93.7 ± 16.1
HbA1c, % 5.7 ± 0.4 4.2 ± 0.3⁎ 5.8 ± 0.4⁎⁎
Inﬂammatory markers
IL6 14.2 ± 4.0 8.6 ± 1.6⁎
TNF-α 21.2 ± 3.6 18.2 ± 2.1
⁎ p b 0.05 between baseline and 4 weeks.
⁎⁎ p b 0.05 between 4 weeks and 3 months.At baseline and at 4 weeks NGT patients had signiﬁcantly better per-
formances at Six Minutes Walking Test than IGT and T2DM patients.
However the three groups had a similar increase of distance walked at
Six Minutes Walking Test after physical training (normal glucose toler-
ance =+166.3 ± 45; IGT =+153.8 ± 64; T2DM=+193.4 ± 61).
At 3 month follow-up visit, the level of compliance to the home-based
exercise training, as expressed through the exercise questionnaire, was
low at 78% of the subjects. Therewas a signiﬁcant increase of bodyweight
and waist circumference compared to both baseline and 4 week values.
Fasting glycemia, fasting insulinemia, and HOMA index (+35%) were all
increased compared to 4 week levels; conversely their levels remained
lower than baseline. Levels of high sensitivity C-Reactive Protein were
similar to 4-week assessment but lower than baseline.
4. Discussion
The ﬁrst ﬁnding of this study is the high prevalence of impaired glu-
cosemetabolism in our sample of CAD patients undergoing intensive CR
early after coronary artery bypass grafting. In our population of subjects
without history of diabetes, less than one third of them had normal glu-
cose tolerance after the ﬁrst OGTT evaluation. Our results are in agree-
ment with similar ﬁndings reported in other studies [10,17]. Boas Soja
et al. [12] showed a prevalence of impaired glucose metabolism of 49–
68% in a cohort of CAD patients undergoing CR. In the Euro Heart Survey
[18] only 29% of the patients with acute CAD and 34% of those with sta-
ble CAD had normal glucose tolerance.
Our study underlines the importance of using OGTT in addition to
fasting plasma glucose for the screening of impaired glucose metabo-
lism in patients with CAD, especially in the context of cardiac rehabilita-
tion/secondary prevention programs. According to our data, many
subjects with impaired glucosemetabolismwould remain undiagnosed
by using fasting plasma glucose alone. In our populationmore than half
of the patients (61%) had a normal fasting glycemia. 30% of the patients
with unrecognized T2DM and 40% of the patients with IGT would have
beenmisclassiﬁed if they had not undergone an OGTT test. Our ﬁndings
are in agreement with those of Norhammar that in the GAMI and
DIGAMI studies underlined the usefulness to perform an OGTT test in
patients with acute ischemic syndromes [8,18]. Similarly Boas Soja
et al. [12] showed that one-ﬁfth of patients with unrecognized T2DM
would remain undiagnosed when using the fasting glucose criteria
alone. Discovering a previously unknown impaired glucosemetabolism
could help physicians to better stratify the risk of patients: IGT is related
to a rate of cardiovascular mortality twice higher than normal glucose
tolerance [1,7,19]. Only in the recent decade blood glucose levels have
been recognized as an independent risk factor for cardiovascular mor-
bidity and mortality [6,20]; several studies showed that raised blood
glucose levels on admission were associated with increased mortality
and congestive heart failure [21–25]. Afterwards, in the context of a car-
diac rehabilitation unit we could identify high risk patients using both
fasting blood glucose and OGTT and select them for amore intensive re-
habilitation program that aims at preventing new acute cardiovascular
events.
Moreover, CABG interventions, like other stressful conditions, may
unmask IGT and diabetes [26]. According to our study post-CABG IGM,
could be often reversible if a comprehensive intervention including ex-
ercise training would be performed. According to the results of second
OGTT determination (post-CR), the proportion of subjects classiﬁed as
T2DM and IGT changed signiﬁcantly. In particular, 64% of the patients
previously classiﬁed as IGT resulted as NGT, while 77% of the patients
previously classiﬁed as T2DM resulted as IGT.
The second ﬁnding of the present study is that an intense exercise
training (six days/week), performed in the contest of a very short
cardiac rehabilitation program (4 weeks), leads to a fast improvement
of glucose metabolism in patients with CAD early after CABG, without
inducing signiﬁcant changes on body weight and waist circumference.
The beneﬁts of exercise in preventing and treating T2DM and
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data come, mostly, from long-term interventions. It has been showed
that exercise training improves glycemic control, body composition,
cardiorespiratory ﬁtness, cardiovascular risk, physical functioning
and well-being in patients with T2DM or IGT. The DANSUK study [12]
demonstrated that a long-term CR intervention, besides the improve-
ment in exercise capacity, improves several metabolic parameters in-
cluding fasting plasma glucose among patients with CAD and T2DM or
IGT.
The causal mechanisms of these exercise training-induced beneﬁts
in T2DMand IGT are complex. They include improvements in insulin re-
sistance [31], increase of insulin dependent glucose uptake [32] and in-
crease of muscle capillarization and blood ﬂow [33].
In this study we focused our attention on insulin resistance as the
leading cause of impaired glucose metabolism in our population. IGT
and T2DM are associated to insulin resistance causing hyperglycemia
on the background of an insulin secretion defect. Moreover, the
cause of insulin resistance can change in different clinical conditions.
In stable subjects undergoing long-term exercise programs the re-
duction of insulin resistance is strongly related to body weight de-
crease. The Finnish Diabetes Prevention Study (DPS) [28] found
that a reduction in body weight achieved through an intensive diet
and exercise program was associated with a signiﬁcant reduction of
the risk of developing T2DM. The reduction of the risk of progression
to diabetes was directly related to the magnitude of the changes in
lifestyle. Conversely in the setting of post-coronary artery bypass
grafting patients, insulin resistance results from an exaggerated re-
lease of stress-hormones and pro-inﬂammatory cytokines related
to the stressful event [26]. The inﬂammatory response has a well
established role in the occurrence of hyperglycemia after cardiac
surgery. IL6 and TNF-α cause insulin resistance in both liver and
skeletal muscles most likely through the modiﬁcation of signaling
properties of insulin receptor substrates [26].
In our population we evidenced a signiﬁcant decrease of insulin re-
sistance after the training period that was signiﬁcantly related to a de-
crease of the blood levels of inﬂammatory cytokines. Probably we
could conclude that in our population physical activity improved glu-
cose metabolism by modulating the inﬂammatory response [34,35].
The lack of changes on body weight conﬁrms that the improvement of
insulin resistance was body weight-independent. The increase of
HOMA index at 12 weeks seems to be related to a low compliance of pa-
tients to the prescribed exercise program.
5. Study limitations
The most important limitation of this study is the lack of a control
group (not exercise training after coronary artery bypass grafting).
However post coronary artery bypass grafting patients who were
ruled out from the CR program were considered not comparable to
the study sample. On the other hand we considered unethical to assign
to a not exercise training group subjects whomet the CR criteria. More-
over because of the lack of a control group we cannot rule out that the
improvement of glucose metabolism observed is due to the longer
time period between CABG and second post CR OGTT compared to the
ﬁrst OGTT.
Other important limitations are a small sample size and a short
follow-up time. Moreover, among factors affecting insulin resistance,
only inﬂammatory cytokines were investigated while we have no data
on stress-hormones.
6. Conclusion
In conclusion, the OGTT is useful to better identify the
glucometabolic state in CAD patients with normal fasting glucose, also
early after coronary artery bypass grafting. So this test should be consid-
ered an essential part of routine care management in cardiacrehabilitation settings. Our data suggest that the leading cause involved
in the improvement of glucose metabolism after training could be the
reduction of insulin resistance.Acknowledgments
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